BCX4430

BCX4430
	File:BCX4430.svg
Systematic (IUPAC) name
	(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
Clinical data
Legal status	Investigational New Drug;
Identifiers
CAS Number	222631-44-9
PubChem	CID: 69211190
ChemSpider	8620968
UNII	OLF97F86A7
Chemical data
Formula	C11H15N5O3
Molecular mass	265.268
	SMILES O[C@H]3[C@H](c2c1ncnc(N)c1nc2)N[C@H](CO)[C@H]3O ;
	InChI InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1 ; Key:AMFDITJFBUXZQN-KUBHLMPHSA-N ;

BCX4430 (Immucillin-A) is an antiviral drug, an adenosine analog^[1] (a type of nucleoside analog).^[2] It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for Hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease and Marburg virus disease. It also shows broad-spectrum antiviral effectiveness against a range of other RNA virus families, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. BCX4430 has been demonstrated to protect against both Ebola and Marburg viruses in both rodents and monkeys, even when administered up to 48 hours after infection,^[1] and development for use in humans is being fast-tracked due to concerns about the lack of treatment options for the ongoing Ebola virus epidemic in West Africa.^[3]

References

↑ ^1.0 ^1.1 Lua error in package.lua at line 80: module 'strict' not found.
↑ Kamat SS, Burgos ES, Raushel FM. Potent inhibition of the C-P lyase nucleosidase PhnI by Immucillin-A triphosphate. Biochemistry. 2013 Oct 22;52(42):7366-8. DOI 10.1021/bi4013287 PMID 24111876
↑ BioWar Lab Helping To Develop Treatment For Ebola. Paul Rodgers, Forbes Magazine. 8 April 2014

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.